Navigation Links
Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
Date:6/20/2013

lished safety profile in other B-cell malignancies. Grade 3 and higher adverse events associated with the treatment of ibrutinib were infrequent with thrombocytopenia and neutropenia seen in 8.6%, and single cases of stomatitis and atrial fibrillation. None of these events led to ibrutinib discontinuation.
  • As of June 3, 2013, 91.4% of patients remain on the study with a minimum of 6 cycles of follow up. The study was extended by an additional 28 patients to further evaluate the safety and efficacy of ibrutinib in WM and a total of 63 patients are now enrolled.
  • "These data suggest that ibrutinib was a highly active and well-tolerated treatment for Waldenstrom's patients in this study, and provide further evidence of the role of BTK in tumor growth," noted Steven Treon, M.D., Ph.D, Director of the Bing Center for Waldenstrom's Research and an attending physician at Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston, MA. "Despite the relatively small patient population, there are currently no approved treatments specifically for Waldenstrom's, so the need for novel therapies such as ibrutinib should not be under-estimated."

    About Ibrutinib
    Ibrutinib is an investigational agent designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

    The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell ly
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
    2. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
    3. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
    4. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
    5. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
    6. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
    7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    8. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
    9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
    10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
    (Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
    (Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
    Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
    ... CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.125 (12.5 cents) per share on the Common ... of record on July 22, 2011. (Logo: ... CVS Caremark is the largest pharmacy health care provider ...
    ... Reportlinker.com announces that a new market ... Growth Hormone Deficiency Global ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth ... 2011 Summary ...
    Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9
    (Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
    (Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
    (Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
    (Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
    (Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
    Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
    ... expert says, , WEDNESDAY, July 22 (HealthDay News) -- When ... kind of snack that matters, but who eats it. , ... women, the healthy-weight women wanted less of the treat over ... non-obese women respond to high-energy, high-density snacks in different ways," ...
    ... , , IRVINE, Calif., July ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced it ... 4, 2009 after the market closes on Tuesday, August 4, 2009. , ... results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will ...
    ... , , , ... July 22 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast ... evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, ...
    ... , , BATON ROUGE, ... manage cleanup efforts in hurricane-ravaged areas. Assisting in the diagnosis and ... which one is practically required to live at the gym and work ... careers are both varied and interesting. . .many of them coming with ...
    ... ... HSA Bank, two innovators in health savings accounts, have announced a new marketing ... easy access to HSA Bank through the My HSA Rewards website to learn ... HSA Bank customers will be given the opportunity to enroll in My HSA ...
    ... The Centers ... much as 4.5 percent by the year 2010. The additional costs could be passed along ... ... likely increase costs to seniors for their Medicare Advantage health insurance plans, in April the ...
    Cached Medicine News:Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 2Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 2Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 4Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 5Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 6Health News:MedVance Institute To Offer New High-Demand Courses 2Health News:MedVance Institute To Offer New High-Demand Courses 3Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 2Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 3Health News:Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010, Says MedicareSupplementPlans.com 2
    ... The SurgiGraphic 6000 lets ... tabletop for precise positioning. ... allows for immediate and ... the C-Arm, making it ...
    ... The REFLEXION 1st MPJ IMPLANT SYSTEM is ... primary reconstruction of the 1st metatarsal phalangeal ... arthritis or revision of a previous arthroplasty. ... three goals: pain relief, superior function and ...
    ... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
    ... The Low Profile Leg Holder provides precise control ... leg rotation, and maximum exposure of the proximal ... Profile Leg Holder can be used on both ... to different heights.,The Low Profile Leg Holder can ...
    Medicine Products: